Cel-Sci Corporation

CVM Healthcare Biotechnology

In the quarter to June 2026, EPS grew 65.4%, free cash flow fell 2.33% and total debt fell 39.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

1.79 0.05 +2.87%
Market cap
$30.6M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
−1.64
Beneish M
−2.35
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.26 1.39 0.60 1.48
Net Debt/EBITDA
1.04 0.27 (0.58) 0.59
Debt/Equity
0.36 0.45 0.64 0.35
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(1.15) (0.50) (0.49) (0.33)
Book value per Share
3.93 1.39 0.84 0.90
Free Cash Flow
(4.68) (4.02) (4.02) (4.03)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates